The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Emavusertib in combination with azacitidine and venetoclax in patients with AML
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the combination of azacitidine and venetoclax with the IRAK4 inhibitor emavusertib for the treatment of acute myeloid leukemia (AML). This triplet combination is currently being investigated in a Phase I clinical trial, with the hopes of improving outcomes for elderly patients with AML who currently have a poor prognosis. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
